Clinical Trial Update: SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma. [Phase 1]

View source ↗

Summary

The SG2501 safety study in subjects with relapsed or refractory hematologic malignancies and lymphoma has been terminated (Phase 1).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Lymphoma

Drugs mentioned

• SG2501

Snippet

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Conditions: Hematological Malignancy, Lymphoma | Phase 1 | Status: TERMINATED